<DOC>
	<DOCNO>NCT02746952</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability several dos UCART19 patient relapse / refractory ( R/R ) acute lymphoblastic leukaemia ( ALL ) chronic lymphocytic leukaemia ( CLL )</brief_summary>
	<brief_title>Dose Escalation Study Evaluate Safety , Tolerability Biological Activity Single Dose UCART19 Patients With Relapsed / Refractory ( R/R ) B-cell Acute Lymphoblastic Leukaemia ( ALL ) Chronic Lymphocytic Leukaemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Male female participant Age ≥ 16 year Patient relapse refractory CD19 positive Bacute lymphoblastic leukaemia ( BALL ) chronic lymphocytic leukaemia Estimated life expectancy ≥ 12 week ( accord investigator 's judgement ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Previous treatment investigational gene cell therapy medicine product CD19 negative Bcell leukaemia Richter 's syndrome Burkitt cell acute leukaemia Previous chemotherapy include biologic/targeted therapy immunological agent ( include blinatumomab ) within 3 week ( nitrosoureas within 6 week ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>